$CRBP
Corbus Pharmaceuticals Holdings Inc

2024 Q1 Form 10-K Financial Statement

#000095017024030133 Filed on March 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.123M $13.91M
YoY Change -31.42% -25.61%
% of Gross Profit
Research & Development $5.761M $6.980M $31.17M
YoY Change -56.97% 11.81% 93.15%
% of Gross Profit
Depreciation & Amortization $151.7K $147.6K $641.0K
YoY Change -16.6% -19.97% -15.99%
% of Gross Profit
Operating Expenses $9.623M $10.10M $45.08M
YoY Change -44.37% -6.42% 13.16%
Operating Profit -$9.623M -$45.08M
YoY Change -44.37% 13.16%
Interest Expense -$677.8K -$2.915M
YoY Change 89.44% 18.39%
% of Operating Profit
Other Income/Expense, Net $2.724M $2.760M $474.0K
YoY Change -708.32% 901.54% -118.87%
Pretax Income -$8.021M -$44.60M
YoY Change -26.27% 5.33%
Income Tax
% Of Pretax Income
Net Earnings -$6.899M -$8.021M -$44.60M
YoY Change -61.12% -26.27% 5.33%
Net Earnings / Revenue
Basic Earnings Per Share -$0.83 -$10.31
Diluted Earnings Per Share -$0.83 -$1.81 -$10.31
COMMON SHARES
Basic Shares Outstanding 10.49M 4.424M 4.328M
Diluted Shares Outstanding 8.311M 4.328M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $120.1M $20.91M $20.91M
YoY Change 171.56% -64.68% -64.68%
Cash & Equivalents $14.10M $13.72M $9.695M
Short-Term Investments $106.0M $7.182M $7.182M
Other Short-Term Assets $1.593M $2.640M $2.640M
YoY Change -2.73% 168.27% 168.27%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $121.7M $23.55M $23.55M
YoY Change 165.34% -60.87% -60.87%
LONG-TERM ASSETS
Property, Plant & Equipment $821.5K $973.2K $4.036M
YoY Change -42.63% -39.69% -26.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $212.8K $690.2K
YoY Change -100.0% 36.99% 9.08%
Total Long-Term Assets $4.048M $4.726M $4.726M
YoY Change -29.97% -22.91% -22.91%
TOTAL ASSETS
Total Short-Term Assets $121.7M $23.55M $23.55M
Total Long-Term Assets $4.048M $4.726M $4.726M
Total Assets $125.7M $28.27M $28.27M
YoY Change 143.48% -57.36% -57.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.082M $3.179M $3.179M
YoY Change 57.36% 46.21% 46.21%
Accrued Expenses $9.398M $11.03M $12.47M
YoY Change 45.3% 83.86% 71.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $12.76M $15.91M $16.21M
YoY Change 154.85% 469.03% 414.73%
Total Short-Term Liabilities $25.92M $31.89M $31.89M
YoY Change 80.54% 152.33% 152.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities $0.00 $44.41K $3.283M
YoY Change -100.0% 100.0% -30.11%
Total Long-Term Liabilities $0.00 $44.41K $3.283M
YoY Change -100.0% -99.72% -84.13%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.92M $31.89M $31.89M
Total Long-Term Liabilities $0.00 $44.41K $3.283M
Total Liabilities $28.78M $35.18M $35.18M
YoY Change -18.21% 5.57% 5.57%
SHAREHOLDERS EQUITY
Retained Earnings -$443.6M -$436.7M
YoY Change 8.24% 11.38%
Common Stock $1.050K $442.00
YoY Change 148.82% 6.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $96.97M -$6.905M -$6.905M
YoY Change
Total Liabilities & Shareholders Equity $125.7M $28.27M $28.27M
YoY Change 143.48% -57.36% -57.36%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$6.899M -$8.021M -$44.60M
YoY Change -61.12% -26.27% 5.33%
Depreciation, Depletion And Amortization $151.7K $147.6K $641.0K
YoY Change -16.6% -19.97% -15.99%
Cash From Operating Activities -$7.967M -$6.009M -$36.10M
YoY Change -47.29% -19.4% -3.85%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$98.24M $10.39M $35.64M
YoY Change -1870.11% -11.81% 18.46%
Cash From Investing Activities -$98.24M $10.39M $35.64M
YoY Change -1870.11% -11.81% 18.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $244.3K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 106.6M -1.905M -2.821M
YoY Change -94412.48% -912.86% 428.57%
NET CHANGE
Cash From Operating Activities -7.967M -6.009M -36.10M
Cash From Investing Activities -98.24M 10.39M 35.64M
Cash From Financing Activities 106.6M -1.905M -2.821M
Net Change In Cash 379.4K 2.475M -3.279M
YoY Change -103.92% -45.72% -59.03%
FREE CASH FLOW
Cash From Operating Activities -$7.967M -$6.009M -$36.10M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$6.009M -$36.10M
YoY Change -19.4% -3.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001595097
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2022 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
CY2022Q4 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2023#DerivativeLiabilitiesCurrent
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-37348
CY2023 dei Entity Registrant Name
EntityRegistrantName
Corbus Pharmaceuticals Holdings, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4348039
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
500 River Ridge Drive
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Norwood
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02062
CY2023 dei City Area Code
CityAreaCode
617
CY2023 dei Local Phone Number
LocalPhoneNumber
963-0100
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023 dei Trading Symbol
TradingSymbol
CRBP
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
34571068
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10493108
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Firm
AuditorFirmId
274
CY2023 dei Auditor Name
AuditorName
EISNERAMPER LLP
CY2023 dei Auditor Location
AuditorLocation
Iselin, New Jersey
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13723681
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17002715
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
7182325
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
42194296
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
192475
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
192475
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2447549
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
791616
CY2023Q4 us-gaap Assets Current
AssetsCurrent
23546030
CY2022Q4 us-gaap Assets Current
AssetsCurrent
60181102
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
477425
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
477425
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
973214
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1613815
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3062920
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3884252
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
212804
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
155346
CY2023Q4 us-gaap Assets
Assets
28272393
CY2022Q4 us-gaap Assets
Assets
66311940
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
300664
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
353323
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3178516
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2173963
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11030506
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5999252
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
39450
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
36868
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1436723
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1280863
CY2023Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
15908214
CY2022Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
2795669
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31894073
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12639938
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15984426
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
44411
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22205
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3238631
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4675354
CY2023Q4 us-gaap Liabilities
Liabilities
35177115
CY2022Q4 us-gaap Liabilities
Liabilities
33321923
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4423683
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4423683
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4171297
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4171297
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
442
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
417
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
429780375
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
425196359
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-436683983
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-392080667
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1556
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-126092
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-6904722
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
32990017
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28272393
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66311940
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31167660
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16136826
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13909641
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18698619
CY2023 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0
CY2022 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
5000000
CY2023 us-gaap Operating Expenses
OperatingExpenses
45077301
CY2022 us-gaap Operating Expenses
OperatingExpenses
39835445
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-45077301
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-39835445
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3389440
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-48773
CY2023 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-2923974
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-2132091
CY2023 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
-2582
CY2022 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
96842
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
11101
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-427436
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
473985
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2511458
CY2023 us-gaap Profit Loss
ProfitLoss
-44603316
CY2022 us-gaap Profit Loss
ProfitLoss
-42346903
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.31
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.31
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.15
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.15
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4327568
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4327568
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4170675
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4170675
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-44603316
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-42346903
CY2023 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
124536
CY2022 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-63647
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
124536
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-63647
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44478780
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42410550
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
69108027
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1
CY2022 us-gaap Proceeds From Issuance Of Redeemable Preferred Stock
ProceedsFromIssuanceOfRedeemablePreferredStock
100
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5719637
CY2022 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
573002
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-63647
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-42346903
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
32990017
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5218
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
109142
CY2023 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
875000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
129745
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3470154
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
124536
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-44603316
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-6904722
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-44603316
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-42346903
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
3470154
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
5719637
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
640601
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
762995
CY2023 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
506166
CY2022 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-124875
CY2023 crbp Gain Loss On Foreign Exchange Rate
GainLossOnForeignExchangeRate
23730
CY2022 crbp Gain Loss On Foreign Exchange Rate
GainLossOnForeignExchangeRate
-648520
CY2023 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
824381
CY2022 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
742478
CY2023 crbp Realized Loss On Investments
RealizedLossOnInvestments
713
CY2022 crbp Realized Loss On Investments
RealizedLossOnInvestments
178222
CY2023 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
-2582
CY2022 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
96842
CY2023 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-21235
CY2023 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1470445
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1573394
CY2023 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
57458
CY2022 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
108961
CY2023 crbp Decrease In Operating Lease Right Of Use Assets
DecreaseInOperatingLeaseRightOfUseAssets
821331
CY2022 crbp Decrease In Operating Lease Right Of Use Assets
DecreaseInOperatingLeaseRightOfUseAssets
724858
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1028283
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-256835
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5031254
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4094160
CY2023 crbp Increase In Other Long Term Liabilities
IncreaseInOtherLongTermLiabilities
-22206
CY2022 crbp Increase In Other Long Term Liabilities
IncreaseInOtherLongTermLiabilities
-0
CY2023 crbp Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1280863
CY2022 crbp Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1136948
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36100473
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37544435
CY2023 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
33884689
CY2022 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
86341894
CY2023 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
69526650
CY2022 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
116421376
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13449
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
8100
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
35641961
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
30074133
CY2023 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
373320
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
452250
CY2023 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
425980
CY2022 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
866865
CY2022 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
1381729
CY2023 us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
2821262
CY2022 us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
1500729
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
244302
CY2023 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
190902
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2820522
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-533615
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3279034
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8003917
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17672615
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25676532
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14393581
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17672615
CY2023 us-gaap Interest Paid Net
InterestPaidNet
2607474
CY2022 us-gaap Interest Paid Net
InterestPaidNet
1969583
CY2023 crbp Issuance Of Common Stock For Conversion Of Convertible Debt
IssuanceOfCommonStockForConversionOfConvertibleDebt
875000
CY2022 crbp Issuance Of Common Stock For Conversion Of Convertible Debt
IssuanceOfCommonStockForConversionOfConvertibleDebt
0
CY2023 crbp Write Off Of Fully Depreciated Property And Equipment
WriteOffOfFullyDepreciatedPropertyAndEquipment
178492
CY2022 crbp Write Off Of Fully Depreciated Property And Equipment
WriteOffOfFullyDepreciatedPropertyAndEquipment
0
CY2023 us-gaap Nature Of Operations
NatureOfOperations
<div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NATURE OF OPERATIONS</span></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corbus Pharmaceuticals Holdings, Inc. (the "Company" or "Corbus") is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, a next-generation ADC that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. The pipeline also includes CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. The Company’s business is subject to significant risks and uncertainties and the Company will be dependent on raising substantial additional capital before it becomes profitable, and it may never achieve profitability.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-436684000
CY2023Q4 crbp Cash And Cash Equivalents And Marketable Debt Securities
CashAndCashEquivalentsAndMarketableDebtSecurities
20906000
CY2023 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
109000000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
477425
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-30
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process of preparing financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and changes in estimates may occur. The most significant estimates are related to stock-based compensation expense (See Note 14), the accrual of research, product development and clinical obligations (see Note 10), and the valuation of warrants</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (see Note 9 and Note 15).</span></p>
CY2023Q4 us-gaap Cash
Cash
4028733
CY2022Q4 us-gaap Cash
Cash
3805156
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
9694948
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
13197559
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13723681
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17002715
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
192475
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
192475
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
477425
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
669900
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
669900
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14393581
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17672615
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has no significant off-balance sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements. The Company may, from time to time, have cash in its U.S. banks in excess of Federal Deposit Insurance Corporation insurance limits and in its foreign banks in excess of their local insurance limits. However, the Company believes the risk of loss is minimal as these banks are large financial institutions.</span></p>
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-44603316
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-42346903
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4327568
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4170675
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.31
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.15
CY2023Q4 crbp Available For Sale Other Investments And Debt Securities Amortized Cost Basis
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAmortizedCostBasis
7183066
CY2023Q4 crbp Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
679
CY2023Q4 crbp Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
-1420
CY2023Q4 crbp Available For Sale Securities Other Investments And Debt Securities
AvailableForSaleSecuritiesOtherInvestmentsAndDebtSecurities
7182325
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
7183066000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
7182325000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
7183066000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
7182325000
CY2022Q4 crbp Available For Sale Other Investments And Debt Securities Amortized Cost Basis
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAmortizedCostBasis
42320040
CY2022Q4 crbp Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q4 crbp Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
-125744
CY2022Q4 crbp Available For Sale Securities Other Investments And Debt Securities
AvailableForSaleSecuritiesOtherInvestmentsAndDebtSecurities
42194296
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
42320040
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
42194296
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
42320040
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
42194296
CY2023 crbp Potential Milestone Payments
PotentialMilestonePayments
1225000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4528546
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4707038
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3555332
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3093223
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
973214
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1613815
CY2023 us-gaap Depreciation
Depreciation
641000
CY2022 us-gaap Depreciation
Depreciation
763000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
1240473
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
1240473
CY2023 us-gaap Lease Cost
LeaseCost
1240473
CY2022 us-gaap Lease Cost
LeaseCost
1240473
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y9M18D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M18D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
1700005
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
1652563
CY2023 crbp Subleases Income
SubleasesIncome
226153
CY2022 crbp Subleases Income
SubleasesIncome
220531
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1747447
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1794889
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1688145
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5230481
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
555127
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
4675354
CY2023 crbp Sublease Agreement Description
SubleaseAgreementDescription
Effective August 26, 2021, the Company entered into a sublease agreement with a third party to sublease 12,112 square feet of the 30,023 square feet currently being leased under one of its two existing lease agreements. The sublease commenced on October 1, 2021 and was scheduled to end on October 31, 2026, however, it is in the process of being terminated early.
CY2021Q3 crbp Sublease Area
SubleaseArea
12112
CY2021Q3 crbp Sublease Area Total
SubleaseAreaTotal
30023
CY2023 crbp Subleases Income
SubleasesIncome
226153
CY2022 crbp Subleases Income
SubleasesIncome
220531
CY2023Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
279585
CY2023Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
291697
CY2023Q4 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
252333
CY2023Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
823615
CY2023 us-gaap Interest Expense Debt
InterestExpenseDebt
3810000
CY2022 us-gaap Interest Expense Debt
InterestExpenseDebt
3097000
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
16303738
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
20000000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2954390
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2954390
CY2023Q4 crbp Accretion Of Debt Discount
AccretionOfDebtDiscount
2558866
CY2022Q4 crbp Accretion Of Debt Discount
AccretionOfDebtDiscount
1734485
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
15908214
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
18780095
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
15908214
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2795669
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15984426
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
17893738
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
17893738
CY2023Q4 crbp Accrued Clinical Operations And Trials Costs Current
AccruedClinicalOperationsAndTrialsCostsCurrent
6274188
CY2022Q4 crbp Accrued Clinical Operations And Trials Costs Current
AccruedClinicalOperationsAndTrialsCostsCurrent
2137317
CY2023Q4 crbp Accrued Product Development Costs Current
AccruedProductDevelopmentCostsCurrent
745447
CY2022Q4 crbp Accrued Product Development Costs Current
AccruedProductDevelopmentCostsCurrent
247500
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2325488
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2224951
CY2023Q4 crbp Accrued Administrative Costs
AccruedAdministrativeCosts
343285
CY2022Q4 crbp Accrued Administrative Costs
AccruedAdministrativeCosts
473376
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1342098
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
916108
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11030506
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5999252
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-44603316
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-42346903
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
10046000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
9376000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
59092710
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
53438141
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
11558247
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
7267176
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
9825596
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
9132973
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5819822
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
8661477
CY2023Q4 crbp Research And Experimental Costs
ResearchAndExperimentalCosts
6367722
CY2022Q4 crbp Research And Experimental Costs
ResearchAndExperimentalCosts
3925743
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
897354
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
503124
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1376351
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1202364
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
94937802
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
84130998
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
94937802
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
84130998
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
23557000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
14523000
CY2023 us-gaap Research And Development Arrangement Contract To Perform For Others Description And Terms
ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
We will amortize these costs for tax purposes over 5 years for R&D performed in the U.S. and over 15 years for R&D performed outside the U.S.
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
10807000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8633000
CY2023Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2022Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0594
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0553
CY2023 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.0028
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.0172
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.0446
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.0408
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0246
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0187
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.0742
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.1109
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0599
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2991
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2477
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-30
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4423683
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4423683
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4171297
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4171297
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
407882
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3470154
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5719637
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3470154
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5719637
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
510870
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
121.9
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
185169
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.9
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
56019
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
107.13
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
22024
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
166.53
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
617996
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
88.99
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
291151
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.15
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
43836
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.85
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
155046
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
68.92
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
1503
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
146.78
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
708762
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
63.96
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M14D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
20216363
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
100.13
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y4M13D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
6243603
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
663007
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
67.78
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y7M20D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
17879915
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
31076
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.84
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
13165
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
4.44
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
17911
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.14
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
62000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M19D
CY2022 crbp Probability Of Decreased Repayment Of Loan
ProbabilityOfDecreasedRepaymentOfLoan
0.35
CY2023 crbp Probability Of Decreased Repayment Of Loan
ProbabilityOfDecreasedRepaymentOfLoan
0.10
CY2023 crbp Probability Of Increased In Repayment Of Loan
ProbabilityOfIncreasedInRepaymentOfLoan
0.40
CY2022 crbp Probability Of Increased In Repayment Of Loan
ProbabilityOfIncreasedInRepaymentOfLoan
0.55
CY2022Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
36868
CY2023 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
-2582
CY2023Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
39450

Files In Submission

Name View Source Status
0000950170-24-030133-index-headers.html Edgar Link pending
0000950170-24-030133-index.html Edgar Link pending
0000950170-24-030133.txt Edgar Link pending
0000950170-24-030133-xbrl.zip Edgar Link pending
crbp-20231231.htm Edgar Link pending
crbp-20231231.xsd Edgar Link pending
crbp-ex10_33.htm Edgar Link pending
crbp-ex21_1.htm Edgar Link pending
crbp-ex23_1.htm Edgar Link pending
crbp-ex31_1.htm Edgar Link pending
crbp-ex31_2.htm Edgar Link pending
crbp-ex32_1.htm Edgar Link pending
crbp-ex32_2.htm Edgar Link pending
crbp-ex97_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img114982030_0.jpg Edgar Link pending
img114982030_1.jpg Edgar Link pending
img114982030_10.jpg Edgar Link pending
img114982030_11.jpg Edgar Link pending
img114982030_12.jpg Edgar Link pending
img114982030_13.jpg Edgar Link pending
img114982030_2.jpg Edgar Link pending
img114982030_3.jpg Edgar Link pending
img114982030_4.jpg Edgar Link pending
img114982030_5.jpg Edgar Link pending
img114982030_6.jpg Edgar Link pending
img114982030_7.jpg Edgar Link pending
img114982030_8.jpg Edgar Link pending
img114982030_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
crbp-20231231_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable